Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0000899243-23-006786 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 | 2023-03-01 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $3.51 | -8,273 | 239.0K | -3% | -$29.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-03-01 | S | D | 8,273 | $3.51 | 238,959 | D | — | — | (F2) The reported price is a weighted average sales price. This represents the price in United States Dollars using the conversion rate on March 1, 2023. These shares were sold in multiple transactions on March 1, 2023 at prices ranging from $4.75 to $4.80 CAD Dollars. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |